ADRA2A is involved in neuro-endocrine regulation of bone resorption

Vid Mlakar a, Simona Jurkovic Mlakar a, Janja Zupan a, Radko Komadina b, Janez Prezelj c, Janja Marc a, *

a Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
b Department for Research and Education, General and Teaching Hospital Celje, Celje, Slovenia
c Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia

Abstract

Adrenergic stimulation is important for osteoclast differentiation and bone resorption. Previous research shows that this happens through β2-adrenergic receptor (AR), but there are conflicting evidence on presence and role of α2A-AR in bone. The aim of this study was to investigate the presence of α2A-AR and its involvement in neuro-endocrine signalling of bone remodelling in humans. Real-time polymerase chain reaction (PCR) and immunohistochemistry were used to investigate α2A-AR receptor presence and localization in bone cells. Functionality of rs553668 and rs1800544 single nucleotide polymorphism SNPs located in α2A-AR gene was analysed by qPCR expression on bone samples and luciferase reporter assay in human osteosarcoma HOS cells. Using real-time PCR, genetic association study between rs553668 A>G and rs1800544 C>G SNPs and major bone markers was performed on 661 Slovenian patients with osteoporosis. α2A-AR is expressed in osteoblasts and lining cells but not in osteocytes. SNP rs553668 has a significant influence on α2A-AR mRNA level in human bone samples through the stability of mRNA. α2A-AR gene locus associates with important bone remodelling markers (BMD, CTX, Cathepsin K and pOC). The results of this study are providing comprehensive new evidence that α2A-AR is involved in neuro-endocrine signalling of bone turnover and development of osteoporosis. As shown by our results the neurological signalling is mediated through osteoblasts and result in bone resorption. Genetic study showed association of SNPs in α2A-AR gene locus with bone remodelling markers, identifying the individuals with higher risk of development of osteoporosis.

Keywords: ADRA2A • osteoporosis • bone • resorption • osteoblast • adrenergic signalling

Introduction

Osteoporosis (OP) has a complex genetic architecture because of numerous underlying molecular processes and genes involved in bone metabolism. Each mechanism is contributing only little to the bone turnover ratio which is a reason why only little variability in BMD can be explained [1, 2]. Our previous research showed that adrenergic receptor α2A (α2A-AR) is up-regulated in osteoporotic bone osteoblasts relative to osteoarthritic bone osteoblasts, suggesting that this type of AR might play an important role in the development of OP [3]. It has been known for some time that AR stimulation results in osteoclast differentiation, which leads, in turn, to bone resorption [4]. There is substantial evidence to suggest that this happens through β2-AR signalling [5–10], since this should be the only AR expressed by osteoblasts [6, 8]. Further studies have shown that beta blockers and agonists have opposite effects on bone mass in adult animals [9, 11, 12]. In contrast to above research, recent publication on mice shows that it is not only β2-AR that plays a role in bone resorption but that the same role is also performed by α2A-AR and α2C-AR. Fonseca et al. showed that double adrenoceptor knockout (ARKO) female mice present a high bone mass phenotype [13]. Moreover, it has also been shown that ARKO mice exhibit lower tartrate-resistant acid phosphatase and receptor activator of NF-κB [13]. The α2A-AR polymorphism 1780G>A (rs553668) was found to be associated with numerous different phenotypes, glucose levels [14], insulin levels and the development of type 2 diabetes [15], obesity and body fat percentage [16], responsiveness to stress [17], endurance status [18], platelet function [19–21] and blood pressure [22]. The precise mechanism of its action is unknown; however, constructs of luciferase reporter and the α2A-AR 3’ UTR region where
polymorphism is located have shown that it probably affects mRNA levels through mRNA stability [23]. Another polymorphism -1291C>G (rs1800544) also showed association with different phenotypes such as attention-deficit/hyperactivity disorder inattentive type [24], tobacco smoking [25], adolescent personality [26], sweet food product consumption [27] and olanzapine treatment [28]. The aim of this study was to investigate whether 2A-AR has a role in human neuro regulation of bone remodelling. In the study, we first addressed the study was to investigate whether 2A-AR presence in bone. Next, above described polymorphisms (rs553668 and rs1800544) were tested for functionality to find suitable genetic markers of 2A-AR gene locus. Next, genetic association study was performed to investigate 2A-AR association with OP and bone turnover markers.

Material and methods

Immunohistochemistry

Bone samples of intertrochanteric trabecular bone from 27 osteoarthritic patients with femoral neck fracture (OP patients), as well as from 21 patients with osteoarthritis (OA) and 14 sex and age-matched autopsy participants (C) as controls including only those where the medical history did not include any disorders affecting bone were obtained (Table 1). Samples were fixed in neutral buffered formalin for a maximum of 24 hrs and decalcified with EDTA. In the cases of the autopsy participants, cross-sections from the femoral head were also collected. Paraffin sections were prepared via a routine procedure at the University of Ljubljana’s Institute of Pathology. Immunohistochemistry was performed on the four samples that showed the highest (OP patient), an intermediate (OA patient) and the lowest (one autopsy participant and one OP patient) gene expression of 2A-AR, respectively. In addition, immunostaining was carried out on one cross-section of the femoral head from the autopsy participant as well. Paraffin sections were dehydrated, rehydrated and microwaved for 10 min. in 0.01 M sodium citrate buffer (pH 6) to release masked epitopes. The immunohistochemistry was hereinafter performed with a Mouse and Rabbit specific HRP/DAB detection IHC kit (ab64264; Abcam, Cambridge, UK) in accordance with the manufacturer’s procedures. Tris buffered saline (TBS), with the addition of Triton X-100 (Sigma-Aldrich, Steinheim, Germany), was used for washing purposes throughout the whole procedure. The primary rabbit polyclonal antibody to 2A-AR (ab65833; Abcam) was diluted 1:100 in TBS buffer and all control slides of each sample were treated with TBS only (negative controls). All slides were incubated overnight at 4°C in a humidified chamber. The specificity of the antibody used had been previously verified in our laboratory on HOS cell culture (data not shown). The tissue sections were counterstained with haematoxylin solution (Thermo Shandon, Pittsburgh, PA, USA) and examined with an Olympus BX50 microscope (Olympus, Hamburg, Germany). The intensity of staining in osteoblasts, lining cells and osteocytes was compared across all samples by two independent, blinded evaluators. Images were acquired using an Olympus XC50 camera and the CellSens Dimension program 1.6.0 (Olympus).

Gene expression association study

The expression of the 2A-AR gene was analysed by quantitative real-time polymerase chain reaction (qPCR) assay in bone samples of Slovenian patients undergoing either hemiarthroplasty or total hip arthroplasty as a consequence of low-energy femoral neck fracture (51 OP patients) or primary hip OA (75 OA patients). Bone tissue samples obtained from autopsy without any diagnosed systemic disease were used as controls (14 C subjects). Patients were included in the study in a consecutive manner over a period of 1.5 years as they were directed to arthroplasty at the Department of Traumatology in the General and Teaching Hospital Celje as a result of receiving a diagnosis of OP or OA. OP was diagnosed by radiologically confirmed low-energy femoral neck fracture and WHO criteria. The diagnosis of OA was established by clinical and radiographic criteria according to the Harris hip score [29]. All OP patients were submitted to arthroplasty within 24 hrs following femoral neck fracture. Bone tissue samples (approximately 1 cm³) were collected during surgical procedures of femoral osteotomy from the trabecular bone at the metaphyseal cutting plane. A proportion of the bone samples was immediately frozen in liquid nitrogen and stored at −80°C until RNA and DNA extraction. The exclusion criteria for the enrolment of OP and OA patients, as applied through the questionnaire, laboratory results and interview, included the following: secondary OP or OA, liver and kidney diseases, endocrinological disorders and medical amnesticness on receiving medications with a known influence on bone metabolism. The study was approved by the Ethical Committee of Republic of Slovenia and all patients gave written informed consent.

DNA and RNA were extracted using a TRI reagent (Sigma-Aldrich Chemie) in accordance with the manufacturer’s procedure. DNA and RNA concentration and purity were evaluated on a ND-1000 (Thermo Scientific, Wilmington, DE, USA). With respect to RNA, the RNA integrity number (RIN) was evaluated using a Bioanalyzer 2100 (Agilent,
Cell lines

All experiments were performed on HOS cell lines (ATCC CRL-1543) grown on DMEM and supplemented with 10% FBS (Gibco, Paisley, UK), 1% L-glutamate (Gibco) and 1% antibiotics/antimycotics (Gibco). Cell lines were passaged on a regular basis, as and when 80–90% confluence was achieved. No more than 20 passages were performed with a single cell line.

Plasmid preparation and luciferase assays

Luciferase reporter assays were performed with pG3-baslic plasmids containing a 3’ UTR region of z2A-AR downstream of the luc gene and an z2A-AR promoter region upstream of the luc gene. All primers were designed based on the ENSEMBL genomic sequence of the z2A-AR gene (ENSST00000280155). All PCRs were performed with a HiFi Polymerase Kit (Qiagen, Hilden, Germany). First, an additional polyclonal site containing EcoRI1 and two AhdI restriction sites followed by another EcoRI site was inserted into the XbaI site (GGAATTCCGACCTGAGTCGACAGATGGTCGAAATTC) downstream of the luc gene to facilitate ADRA2A 3’ UTR cloning. Next, ATAAAGCTTGGAGATAGG AGAAGGCC forward (containing a BglII restriction site) and TTAAAGCTT GAAGGATCAGCTCTCCAGGA (containing a HindIII restriction site) reverse primers were used to amplify the 5’ promoter region of z2A-AR.

After obtaining the pG3-baslic with the z2A-AR promoter region, the 3’UTR of z2A-AR from a heterozygous individual (polymorphism A/G rs553668) was amplified using the following primers: GTAGACTCAGC CGTACTGCAAG forward and GAAACTGTACAGTTTGGCACGG reverse [17]. The PCR product was cloned into a TOPO TA PCR cloning vector (Invitrogen, Carlsbad, CA, USA). Colonies were selected according to A or G genotype to obtain both z2A-AR 3’ UTR alleles. The inserted PCR was excised from the TOPO TA 4.0 vector using EcoR1 and cloned downstream of the luc gene into the newly established EcoR1 restriction site. The final plasmid constructs were sequenced to verify the sequence identity and orientation upstream and downstream of the luc gene. The HT multidetection microplate reader (Fisher Scientific, Pittsburgh, PA, USA) was used to produce forward- and reverse-sequenced clones downstream of the luc gene. Reverse primers were used to produce forward- and reverse-sequenced clones upstream of the luc gene. Sequencing was performed with the DTCS quick sequencing kit (Beckman Coulter, High Wycombe, UK) and reactions were separated on a GeXP Genomic Analyser (Beckman Coulter) in accordance with the manufacturer’s instructions.

Functional assays were carried out by plating cells at a density of 35,000 cells/well in 24-well tissue culture plates. After 24 hrs, the cells were transfected in six replicates with a mixture of Fugene HD transfection reagents (Roche Diagnostics, Mannheim, Germany) at a ratio (ml reagent:ml DNA) of 3:2, DMEM and 475 ng DNA/well and an additional 25 ng/well of a pRL-TK control vector reporter. Cells were harvested 48 hrs post transfection, and the luciferase assay performed with a Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA). Luminescence was measured using a Bio-TEK Synergy HT multidetection microplate reader (Fisher Scientific, Pittsburgh, PA, USA).

Subjects

We evaluated 661 Slovenian people who were referred to the outpatient departments of the University Medical Centre in Ljubljana, the General and Teaching Hospital in Celje or the University Centre Maribor for BMD measurement. BMD measurements at the lumbar spine (L2-L4) BMD-ls, total hip BMD-hip and femoral neck BMD-fn were performed by dual-energy X-ray absorptiometry (QDR-4500; Hologic, Inc., Waltham, MA, USA) in Ljubljana, Celje and Maribor. Cross-calibration study of the precision of measurements between the centres had previously been performed and a correction factor was not considered necessary. Each patient was examined clinically and routine biochemical tests were performed to exclude systemic and metabolic bone diseases other than primary OP. Subjects who had previously taken any drug known to influence bone metabolism were excluded from the study. Biochemical markers of bone turnover were measured in subgroups of subjects. Blood samples were collected between 8.00 a.m. and 10.00 a.m. after an overnight fast. The plasma and serum samples were analysed in a routine laboratory using standard procedures as outlined by the manufacturers. Osteocalcin (OC) in heparin plasma was measured by means of a solid-phase, two-site chemiluminescent enzyme-labelled immunometric assay (Immulite Osteocalcin, Diagnostic Product Corporation, Los Angeles, CA, USA). Serum bone alkaline phosphae (sBALP) was measured by radioimmunoassay (Tandem-R Ostase, Beckman Coulter, Fullerton, CA, USA). Serum C-terminal
cross-linking telopeptides of type I collagen (CTX), osteoprotegerin and cathepsin K were measured by enzyme immunoassay (Serum Cross-Laps ELISA, Nordic Bioscience Diagnostics A/S, Herlev, Denmark, Osteoprotegerin ELISA, Biomedica, Vienna, Austria, and Cathepsin K ELISA, Biomedica, respectively). The study was approved by the Ethical Committee of the Republic of Slovenia and written informed consent was obtained from each patient participating in the study.

Genotyping on blood samples

DNA was isolated from peripheral blood leucocytes using a Flexigene kit (QiAgen) in accordance with the manufacturer’s protocol. Genotyping was performed with 5x HOT FIREPol® Probe qPCR Mix Plus (Solis BioDyne, Tartu, Estonia) and 10 ng of genomic DNA and the TaqMan genotyping assays C___96424_20 for rs553668 and C___7611979_10 for rs1800544 (both Applied Biosystems) respectively, in line with the manufacturer’s protocol. Allelic discrimination was performed on LightCycler 480® (Roche Diagnostics, Switzerland) employing the following protocol: 1 cycle of 15 min. at 95°C, followed by 45 cycles at 95°C for 15 sec., 60°C for 60 sec. and 4 min. at 40°C. An end-point genotyping program was used to call genotypes automatically.

Statistical analysis and bioinformatics

Comparisons between genotype, and allele frequencies in subject subgroups were performed with a chi-squared test or Fisher’s exact probability test. The degree of linkage disequilibrium (LD), denoted as \( D' \) and \( r^2 \), between both SNPs was calculated using EMLD software (Qiqing Huang, University of Texas, Houston, TX; https://cge.manderson.org/~qhuang/Software/pub.htm). The distribution of variables was assessed using the Shapiro–Wilks test and logarithmic transformation was used for variables that did not meet the normality assumption. The effects of genotypes, and alleles on BMD and biochemical markers of bone turnover were evaluated by means of the general linear model (GLM) adjusted for age, sex and body mass index (BMI) in all study subgroups. An LSD post hoc adjustment for multiple comparisons was used to find the differences within the genotype subgroups. The effects of the studied alleles on fracture risk were examined by logistic regression analysis in the group of all participants and, subsequently, in subgroups of elderly people, men and postmenopausal women. The model included the studied alleles (one or both alleles versus no allele under study), age (in years), BMI (in kg/m²) and femoral neck BMD (in g/cm²). The significance threshold was set at 0.05. SPSS Statistics version 21 (IBM, Chicago, IL, USA) was used for all statistical analyses. The power of our study was 61% to detect a 0.080 g/cm² difference in BMD between the genotype and haplotype subgroups and 69.3–98.2% to discover a significant difference in the odds ratio of alleles between fracture patients and the no fracture controls [32].

The association of \( \alpha \)-2A-AR genotypes with \( \alpha \)-2A-AR gene expression in the study group as a whole was evaluated using the \( \Delta \Delta \text{CT} \) test once the normality of distribution had been confirmed. TargetScan 6.2 (Whitehead Institute, Cambridge, MA, USA) [33] and miRANDA programs [34] were used to search for conserved miRNA sites in the region of the 1780G>A polymorphism. The Unafold 4.6 [35] program was used to predict the secondary structure of RNA and estimate the structure’s stability by calculation of its free energy.

Results

Immunohistochemistry

To understand whether \( \alpha \)-2A-AR could be involved in neuro-endocrine signalling, its presence in human bones was investigated using immunohistochemistry. In addition, we have been suggested that since ARKO knockout mice show higher bone phenotype, we might see the difference in \( \alpha \)-2A-AR distribution in bones of different density. As a result of the qualitative and at best semi-quantitative nature of immunohistochemistry, we used the method only to investigate \( \alpha \)-2A-AR localization within bone sample. Immunohistochemistry was performed on the four bone samples showing different \( \alpha \)-2A-AR expression according to real-time PCR (see Table 1 for average \( \alpha \)-2A-AR mRNA expression), the highest (OP patient – relative expression of 1.7388), an intermediate (OA patient – relative expression 1.0407) and the lowest (autopsy participant and one OP patient – relative expression 0.7752 and 0.8840 respectively). This was performed to understand whether the difference in \( \alpha \)-2A-AR mRNA expression was because of different cells expressing \( \alpha \)-2A-AR or because of difference in numbers and/or expression of \( \alpha \)-2A-AR on the cells carrying the receptor. The results show that \( \alpha \)-2A-AR is present on osteoblasts and lining cells but not osteocytes (Fig. 1A and C) regardless of the twofold difference in \( \alpha \)-2A-AR mRNA expression level between these two samples. The most intensive staining was observed in the sample from the OP patient with the highest \( \alpha \)-2A-AR gene expression, where cuboidal shaped osteoblasts with intensive \( \alpha \)-2A-AR staining were present (Fig. 1A). The OP sample with the lowest \( \alpha \)-2A-AR gene expression (Fig. 1C) also showed intensive staining in lining cell and osteoblasts. Both OP samples contained \( \alpha \)-2A-AR negative osteocytes (Fig. 1A and C). OA and autopsy sample (Fig. 1B and D) did not include any cuboidal shaped osteoblasts. Individual osteocytes were positive for \( \alpha \)-2A-AR in trabecular bone of autopsy sample (Fig. 1D). To examine \( \alpha \)-2A-AR distribution in a denser bone, a cross-section of the femoral head from the autopsy participant was performed (Fig. 2). Negative \( \alpha \)-2A-AR staining for osteocytes in the cortical and trabecular bones in the cross-section of the autopsy sample was observed (Fig. 2A and B). All negative controls performed did not show unspecific binding of secondary antibody. Results suggest that \( \alpha \)-2A-AR is predominantly expressed by osteoblasts and lining cells. Some osteocytes of trabecular bone may show \( \alpha \)-2A-AR expression but not osteocytes of cortical bones such as femoral head. Level of expression does not appear to be because of the different cells expressing \( \alpha \)-2A-AR, but rather because of the number of osteoblasts and lining cells in samples in comparison to other cells and/or \( \alpha \)-2A-AR mRNA expression level of these two cell lineages.

Gene expression association study

Gene expression study was performed to further support results that \( \alpha \)-2A-AR is expressed in bone. Second, we tested the association of rs553668 and rs1800544 SNPs to find genetic factors that influence \( \alpha \)-2A-AR expression, useful for further genetic analysis. Of 140
samples, 113 samples tested positive for the presence of α2A-AR mRNA using real-time PCR (Table 1), supporting above obtained immunohistochemistry result showing α2A-AR is indeed present in bone tissue. Next, association between amount of α2A-AR transcript and rs553668 and rs1800544 was investigated to test functionality of both SNPs in α2A-AR gene locus. Significant difference in the expression of α2A-AR and presence of the rs553668 was observed (Fig. 3) when performing univariate statistical model adjusted for age, sex, height, weight and disease ($P = 0.003$). Statistical significant result was obtained also when no adjustment was made with slightly higher $P$-value of 0.006, showing that co-variables do not have much influence on α2A-AR gene expression. The highest expression was shown in AA genotype carriers, which was significantly different from the expression in GG genotype carriers; namely, by 10%. Heterozygote carriers showed the lowest expression (lower by 15% and 6% compared to AA and GG genotype carriers, respectively, Fig. 3). The number of AA genotype samples was too small ($N = 5$) to draw complete conclusions. To clarify the effect of the A allele on gene expression, we continued with a Luciferase assay. Importantly no statistically significant difference in α2A-AR gene expression between male and
female was observed. No statistically significant difference in α2A-AR gene expression was observed between disease groups although the OP group showed slightly but not statistically significant difference in comparison to OA or control group (Table 1).

The association between the gene expression of the α2A-AR and rs1800544 SNP was not significant in this study group (P = 0.644).

Luciferase assay and bioinformatics

Luciferase reporter assay was performed to further support the evidence of rs553668 SNP functionality in osteoblasts. We constructed two novel plasmids containing 3’ UTR region of the α2A-AR cloned behind the luciferase reporter gene in pGfr-Basic to study the rs553668 SNP influence on mRNA stability. Each plasmid contained either G or A variant of rs553668 SNP. Transient transfections with two different plasmids were performed for an mRNA stability evaluation. Forty-eight hours post transfection, Renilla and firefly luciferase activities were measured and expressed as a ratio of firefly to Renilla activity. The relative ratio of luciferase activity was 1.000 and 0.896 in the A and G genotypes respectively (Fig. 4), with the difference between the ratios being statistically significant (P < 0.012). This result supports the in vivo measurement of α2A-AR gene expression, where lower amount of mRNA was observed in individuals carrying G variant of rs553668 SNP.

A section of 3’ UTR was analysed using TargetScanHuman and miRANDA programs to evaluate if miRNA binding might play a role in α2A-AR mRNA stability. No binding site for miRNA was found in the vicinity of the polymorphic site. Next, the influence of rs553668 SNP on α2A-AR mRNA secondary structure formation was evaluated. Two distinct but equally stable (ΔG = –2.4 kcal/mol) structures were noted (Fig. 4) suggesting the possibility that rs553668 SNP could function through difference in secondary structure of 3’ UTR of α2A-AR mRNA.

Genotype association study

To investigate the possible association of α2A-AR gene locus with BMD and other biochemical turnover markers and to identify individuals at possible higher risk for OP genotype association study was performed. Above confirmed functional SNP rs553668 and SNP rs1800544 both in LD, were used. Rs1800544 did not show functionality on the level of α2A-AR mRNA. It was, nevertheless, included in...
the genetic association study because it was identified as a tag SNP of the α2A-AR gene locus, with a frequency favourable for genetic association study. The frequencies of rs553668 and rs1800544 SNPs in the α2A-AR gene were determined by screening DNA samples from 661 Slovenian individuals, divided into four subgroups with characteristics as presented in Table 2.

The distributions of genotypes for both SNPs are shown in Table 3. The genotype frequencies for each polymorphism were consistent with the Hardy–Weinberg distribution (P > 0.05) as a whole and in all subgroups. There were no significant differences in both SNPs genotypes between subgroups (P > 0.05). The genotype frequencies were similar to those in the HapMap for rs553668, while rs1800544 showed a higher frequency of the minor genotype GG (1.4–5.8% versus 0%) in our study groups compared to PubMed data for the European population (NCBI dbSNP Build 141, http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=rs1800544). Both SNPs were in LD, with r² = 0.56 and D’ = 0.986.

The results of GLM analysis are presented in Table 3. Significant correlations were observed between α2A-AR gene locus and BMD at lumbar spine in postmenopausal women and markers of bone turnover in subgroups of subjects.

### Table 2 Anthropometric characteristics of the study population for α2A-AR genotyping

|                      | Premenopausal women (N = 53) | Postmenopausal women (N = 429) | Elderly men (N = 108) | OP patients (N = 71) |
|----------------------|-----------------------------|--------------------------------|-----------------------|----------------------|
| Female/male          | 53/0                        | 429/0                          | 0/108                 | 54/17                |
| Age (years)          | 45.7 ± 4.8                  | 61.9 ± 8.5                     | 67 ± 6                | 78 ± 7               |
| Body mass index (kg/m²) | 24.5 ± 4.2                  | 28.2 ± 5.0                    | 28.0 ± 3.5            | 26.1 ± 3.6           |
| Hip BMD (g/cm²)      | 0.924 ± 0.089               | 0.914 ± 0.136                 | 0.809 ± 0.151         | 0.597 ± 0.097        |
| T score (hip)        | −0.2 ± 0.7                  | −0.4 ± 1.0                    | −1.2 ± 1.1            | −2.6 ± 0.9           |
| Femoral neck BMD (g/cm²) | 0.783 ± 0.076              | 0.763 ± 0.120                | 1.021 ± 0.160         | 0.678 ± 0.125        |
| T score (FN)         | −0.7 ± 0.7                  | −1.0 ± 1.0                    | −0.3 ± 1.0            | −2.4 ± 0.9           |
| Lumbar spine L2-L4 BMD (g/cm²) | 1.003 ± 0.117          | 0.974 ± 0.137                | 1.061 ± 0.189         | 0.862 ± 0.174        |
| T score (LS)         | −0.6 ± 1.0                  | −0.8 ± 1.2                    | −0.4 ± 1.6            | −1.8 ± 1.6           |

Values are mean ± SD.
BMD, bone mineral density; FN, femoral neck; LS, lumbar spine.

### Table 3 Results of A→G (rs553668) and C→G (rs1800544) genotyping analysis and their association with BMD and biochemical markers of bone turnover in subgroups of subjects

|                      | A→G (%)                  | C→G (%)                  | A→G (rs553668)       | C→G (rs1800544)     |
|----------------------|--------------------------|--------------------------|----------------------|----------------------|
| Premenopausal women  | G/G 37 (69.8)            | G/C 28 (52.8)            | Cathepsin K (P = 0.014) | NS                   |
|                      | G/A 16 (30.2)            | C/G 22 (41.5)            | AG: 18.3 ± 19.2 pmol/l | BMD-ls (P = 0.027)  |
|                      | A/A 0 (0)                | G/G 3 (5.7)              | GG: 3.5 ± 19.1 pmol/l | GG: 0.802 ± 0.155 g/cm² |
|                      |                          |                          |                      | GC: 0.880 ± 0.157 g/cm² |
| Postmenopausal women | G/G 307 (71.6)           | G/C 257 (59.9)           | NS                   | sCTX (P = 0.012)    |
|                      | G/A 114 (26.6)           | C/G 147 (34.3)           |                      | GC: 3305 ± 988 pmol/l |
|                      | A/A 8 (1.9)              | G/G 25 (5.8)             |                      | CC: 1689 ± 949 pmol/l |
| Elderly men          | G/G 87 (80.6)            | G/C 79 (73.1)            | NS                   | sBALP (P = 0.053)   |
|                      | G/A 20 (18.5)            | G/C 26 (24.1)            |                      | GC: 9.6 ± 2.9 µg/l  |
|                      | A/A 1 (0.9)              | G/G 3 (2.8)              |                      | CC: 7.2 ± 2.9 µg/l  |
| OP patients          | G/G 60 (84.5)            | G/C 49 (69.0)            | pOC (P = 0.009)      |                      |
|                      | G/A 10 (14.1)            | G/C 21 (29.6)            | AG: 11.8 ± 5.2 µg/l  |                      |
|                      | A/A 1 (1.4)              | G/G 1 (1.4)              | GG: 5.4 ± 5.2 µg/l   |                      |

Values are number of frequencies (percentages) and mean ± SD. Differences were obtained using general linear model.
NS, P > 0.05.
BMD-ls, lumbar spine bone mineral density; sCTX, serum C-terminal crosslinking telopeptides of type I collagen; pOC, plasma osteocalcin; sBALP, serum bone alkaline phosphatase concentration; cathepsin K, serum cathepsin K concentration.
over sCTX in elderly men, cathepsin K in premenopausal women, pOC and borderline with sBALP in OP patients.

Discussion

In this study, the further evidence for involvement of \( \alpha2A \)-AR signalling in neuro-endocrine regulation of bone remodelling is presented. This study is the first to provide evidence on the level of human bone tissue, using immunohistochemical, and functional characterization of genetic polymorphisms influence on the level of \( \alpha2A \)-AR transcript. The research shows that not only \( \beta2 \)-AR is involved in neurological signalization but also that \( \alpha2A \)-AR will have to be considered in the future.

First evidence of \( \alpha2A \)-AR involvement in neuro-endocrine regulation of bone remodelling was obtained by identification of bone cells possessing \( \alpha2A \)-AR. The results show that \( \alpha2A \)-AR is present on osteoblasts and lining cells (Fig. 1A and C). The receptor may be present on individual osteocytes of trabecular bone (Fig. 1B and D), but we have not detected the receptor on osteocytes of denser cortical bone (Fig. 2A and B). This result is in agreement with a recent report on ARKO knockout mice that showed increased bone mass [13]. To further support the data on \( \alpha2A \)-AR expression in human osteoblasts and lining cells, real-time PCR was performed to detect gene transcript in bones. Results obtained on 140 bones samples show presence of \( \alpha2A \)-AR mRNA transcript in 105, supporting conclusion that \( \alpha2A \)-AR receptor is expressed in bone remodelling cells – osteoblasts and lining cells. Because histological results did not contain osteoclasts the conclusion whether they contain \( \alpha2A \)-AR was not possible. To provide further evidence of \( \alpha2A \)-AR association with bone metabolism, genetic association study was performed. Prior to that, role of two SNPs rs553668 and rs1800544 was investigated to provide evidence of their functionality. The results on rs553668 SNP show that variant G appears to have destabilizing effect on \( \alpha2A \)-AR mRNA probably through formation of different secondary structure and not through mRNA mediated degradation process as there appear to be no mRNA binding sites in vicinity of polymorphic site. The rs1800544 did not correlate with \( \alpha2A \)-AR mRNA expression, therefore no further luciferase reporter tests were carried out. Subsequent genetic association study using both SNPs showed significant association of \( \alpha2A \)-AR gene locus and BMD and markers that reflect bone metabolism. The result supports the conclusion that \( \alpha2A \)-AR present on osteoblasts may be actively involved in bone remodelling. In support of these results, the same extensive chromosome 10q24-q26 location, containing multiple genes, has previously been shown to be associated with OP and BMD [1].

The precise pathway of \( \alpha2A \)-AR action is unknown. Our results suggest action through osteoblasts and/or lining cells because they carry the receptor. Several mechanisms of action might be envisaged. Signalling may either result in apoptosis and/or inhibition of osteoblast proliferation or in stimulation of osteoclast differentiation, tipping the bone remodelling balance in favour of bone resorption. Evidence from the study on ARKO mice shows latter might be more plausible, since decreased expression of RANKL was observed in mutant mice [13]. Similar findings were observed on \( \beta2 \)-AR receptors. Osteoblasts having viable \( \beta2 \)-AR receptor were able to stimulate osteoclast formation in contrast to \( \beta2 \)-AR null osteoblast. The signalling was mediated through ATF4 phosphorylation and the main ligand for \( \beta2 \)-AR was leptin [6, 8]. Authors also claimed that \( \beta2 \)-AR is the only AR expressed by osteoblast [6, 8] which would be in contrast to our and other [13] results. However, it appears from their manuscript that expression of \( \alpha2A \), \( \alpha2B \) and \( \alpha2C \)-AR receptors was not investigated on culture of primary mouse osteoblasts [6, 8], therefore, our study is the first to investigate and prove their presence in human bones. The finding of other ARs on osteoblasts is interesting because both knockout mice (ARKO and \( \beta2 \)-AR) produce similar high bone phenotype. The result points to possible interaction of ARs. One possible explanation of why similar bone phenotypes were obtained when knocking out either of ARs might involve well known process of ARs dimerization [36]. The other more indirect explanation may involve receptor cross-talk that showed how \( \beta2 \)-AR stimulation resulted in increased \( \alpha2A \)-AR internalization on the same neuron cell [37] or its desensitization by recruiting GRK protein to plasma membrane [38]. Although the precise mechanism of action on osteoblasts and lining cells remains to be elucidated our finding of new ARs in bone might have possible clinical implications. The use of beta blockers has for some time been considered as a treatment option for bone fracture healing and treatment of OP [39]. Because signalling through \( \alpha2A \)-AR appears to have similar effect on bone as \( \beta2 \)-AR, antagonists and agonists of \( \alpha2A \)-AR should be explored for their beneficial and detrimental effect on bone.

In conclusion, the study presents further evidence based on human samples that \( \alpha2A \)-AR receptors are important in osteoblast neuro-endocrine signalling, bringing a new player repetition along with already known \( \beta2 \)-AR. Although the precise pathway of events remains to be elucidated, it looks like the neurological signal of bone remodelling is mediated through osteoblasts and/or lining cells which seem to express most of the \( \alpha2A \)-AR of bone remodelling cells. The study also shows that functional polymorphism in 3’ UTR of \( \alpha2A \)-AR gene affects its mRNA stability and is associated with bone turnover markers.

Acknowledgements

The authors thank Mateja Prunk and Manca Ogrič for their excellent technical contribution, Barbara Ostanek, Simona Mencej-Bedrač, Jana Dragojević, Zoran Trost and Darja Bitenc-Logar for their valuable help on collecting patients’ samples, Gregor Haring for providing autopsy bone samples, Franci Vindisar for femoral neck fracture samples, Rihard Trebše for bone tissue samples from osteoarthritic patients, and the Slovenian Research Agency for financial support through grant J3-2330.

Conflicts of interest

Vid Mlakar, Simona Jurkovič Mlakar, Janja Zupan, Radko Komadina, Janez Preželj and Janja Marc declare that they have no conflict of interest.
Author contribution
VM: plasmid constructs, luciferase assays, study design, drafting the manuscript. SJM: expression analysis, statistical analysis and writing. JZ: immunohistochemistry, genotyping, statistical analysis. RK: sample collection/analysis and critical review. JP: sample collection/analysis and critical review. JM: manuscript writing and critical review.

References
1. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012; 44: 491–501.
2. Raiston SH, de Crombrugghe B. Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev. 2006; 20: 2492–506.
3. Trost Z, Trebse R, Prezelj J, et al. A micro-array based identification of osteoporosis-related genes in primary culture of human osteoblasts. Bone. 2010; 46: 72–80.
4. Takeuchi T, Tsuiboi T, Arii M, et al. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem Pharmacol. 2001; 61: 579–86.
5. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000; 100: 197–207.
6. E1efe1riou F, Ahn JD, Takeda S, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005; 434: 514–20.
7. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003; 423: 549–55.
8. Takeda S, E1efe1riou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002; 111: 305–17.
9. Togari A. Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc Res Tech. 2002; 58: 77–84.
10. Togari A, Arai M, Kondo A. The role of the sympathetic nervous system in controlling bone metabolism. Expert Opin Ther Targets. 2005; 9: 931–40.
11. Bonnet N, Benhamou CL, Beaupied H, et al. Doping dose of salbutamol and exercise: deleterious effect on cancellous and cortical bones in adult rats. J Appl Physiol. 2007; 102: 1502–9.
12. Bonnet N, Benhamou CL, Brunet-Imbault B, et al. Severe bone alterations under beta2 agonist treatments: bone mass, microarchitectural and strength analyses in female rats. Bone. 2005; 37: 622–33.
13. Fonseca TL, Jorgetti V, Costa CC, et al. Double disruption of alpha2A- and alpha2C-adrenoceptors results in sympathetic hyperactivity and high-bone-mass phenotype. J Bone Miner Res. 2011; 26: 591–603.
14. Ukkola O, Tremblay A, Bouchard C. Beta-2 adrenergic receptor variants are associated with subcutaneous fat accumulation in response to long-term overfeeding. Int J Obes Relat Metab Disord. 2001; 25: 1604–8.
15. Rosengren AH, Jokubka R, Tijjar D, et al. Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Science. 2010; 327: 217–20.
16. Lima JJ, Feng H, Duckworth L, et al. Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations. Metabolism. 2007; 56: 757–65.
17. Finley JC Jr, O’Leary M, Wester D, et al. A genetic polymorphism of the alpha2A-adrenergic receptor increases autonomic responses to stress. J Appl Physiol. 2004; 96: 2231–9.
18. Wolfarth B, Rivera MA, Oppert JM, et al. A polymorphism in the alpha2a-adrenoceptor gene and endurance athlete status. Med Sci Sports Exerc. 2000; 32: 1709–12.
19. Freeman K, Farrow S, Schmaier A, et al. Genetic polymorphism of the alpha 2-adrenergic receptor is associated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans. Am J Hypertens. 1995; 8: 863–9.
20. Martinez C, Anton AI, Corral J, et al. Genotype-phenotype relationship for six common polymorphisms in genes affecting platelet function from 286 healthy subjects and 160 patients with mucocutaneous bleeding of unknown cause. Br J Haematol. 2009; 146: 95–103.
21. Yabe M, Matsubara Y, Takahashi S, et al. Identification of ADR2A polymorphisms related to shear-mediated platelet function. Biochem Biophys Res Commun. 2006; 347: 1001–5.
22. Rana BK, Insel PA, Payne SH, et al. Population-based sample reveals gene-gender interactions in blood pressure in White Americans. Hypertension. 2007; 49: 96–106.
23. Small KM, Brown KM, Seman CA, et al. Complex haplotypes derived from noncoding polymorphisms of the intronless alpha2A-adrenergic gene diversity receptor expression. Proc Natl Acad Sci USA. 2006; 103: 5472–7.
24. Schmitz M, Denardin D, Silva TL, et al. Association between alpha-2a-adrenergic receptor gene and ADHD inattentive type. Biol Psychiatry. 2006; 60: 1028–33.
25. Prestes AP, Marques FZ, Hutch M, et al. Tobacco smoking and the ADR2A C-1291G polymorphism. J Neural Transm. 2007; 114: 1503–6.
26. Maestu J, Allik J, Merenakk L, et al. Associations between an alpha 2A adrenergic receptor gene polymorphism and adolescent personality. Am J Med Genet B Neuropsychiatr Genet. 2008; 147B: 418–23.
27. Maestu J, Villa I, Park J, et al. Human adrenergic alpha 2A receptor C-1291G polymorphism leads to higher consumption of sweet food products. Mol Psychiatry. 2007; 12: 820–1.
28. Park YM, Chung YC, Lee SH, et al. Weight gain associated with the alpha2a-adrenergic receptor –1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet. 2006; 141B: 394–7.
29. Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am. 1995; 51: 737–55.
30. Logar DB, Komadina R, Prezelj J, et al. Expression of bone resorption genes in osteoarthritis and in osteoporosis. J Bone Miner Metab. 2007; 25: 219–25.
31. Zupan K, Komadina R, Marc J. The relationship between osteoarthritis and anti-osteoarthritis pro-inflammatory cytokines differs in human osteoprotic and osteoarthritic bone tissues. J Biomed Sci. 2012; 19: 28.
32. Faul F, Erdfelder E, Buchner A, et al. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009; 41: 1149–60.
33. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120: 15–20.
34. Griffiths-Jones S, Saini HK, van Dongen S, et al. miRBase: tools for microRNA genomics. *Nucleic Acids Res*. 2008; 36: D154–8.

35. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res*. 2003; 31: 3406–15.

36. Hein L. Adrenoceptors and signal transduction in neurons. *Cell Tissue Res*. 2006; 326: 541–51.

37. Cottingham C, Lu R, Jiao K, et al. Cross-talk from beta-adrenergic receptors modulates alpha2A-adrenergic receptor endocytosis in sympathetic neurons via protein kinase A and spinophilin. *J Biol Chem*. 2013; 288: 29193–205.

38. Bawa-Khalfe T, Altememi GF, Mandyam CD, et al. The presence of beta2-adrenoceptors sensitizes alpha2A-adrenoceptors to desensitization after chronic epinephrine treatment. *BMC Pharmacol*. 2007; 7: 16.

39. Graham S, Hammond-Jones D, Gamie Z, et al. The effect of beta-blockers on bone metabolism as potential drugs under investigation for osteoporosis and fracture healing. *Expert Opin Investig Drugs*. 2008; 17: 1281–99.